
CITATION REPORT List of articles citing



DOI: 10.1136/ard.55.3.187 Annals of the Rheumatic Diseases, 1996, 55, 187-9.

Source: https://exaly.com/paper-pdf/27518691/citation-report.pdf

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
84	Low-dose aspirin may precipitate MI. <i>Reactions Weekly</i> , 1996 , &NA, 5	Ο	
83	Current concepts in monitoring patients on antimalarials. <i>Australian and New Zealand Journal of Ophthalmology</i> , 1998 , 26, 101-3		14
82	Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. <i>Eye</i> , 1998 , 12 (Pt 6), 907-9	4.4	36
81	Long-term effectiveness of antimalarial drugs in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 1998 , 57, 582-7	2.4	72
80	Ocular toxicity and hydroxychloroquine: guidelines for screening. <i>British Journal of Dermatology</i> , 1999 , 140, 3-7	4	61
79	The use of antimalarials in dermatology. Journal of Dermatological Treatment, 2000, 11, 185-194	2.8	2
78	Management of patients undergoing hydroxychloroquine (Plaquenil) therapy. <i>Australasian journal of optometry, The</i> , 2000 , 83, 32-36	2.7	8
77	Comparative tolerability of treatments for juvenile idiopathic arthritis. <i>BioDrugs</i> , 2000 , 14, 159-83	7.9	6
76	Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?. <i>American Journal of Ophthalmology</i> , 2001 , 131, 761-6	4.9	77
75	Early hydroxychloroquine macular toxicity. Arthritis and Rheumatism, 2001, 44, 1959-61		27
74	Antimalarial therapy: a panacea for mild lupus?. <i>Lupus</i> , 2001 , 10, 148-51	2.6	26
73	Le dBistage de la toxicitdes antipaludens : notions courantes. <i>Canadian Journal of Ophthalmology</i> , 2002 , 37, 331-334	1.4	0
72	Screening for antimalarial toxicity: current concepts. <i>Canadian Journal of Ophthalmology</i> , 2002 , 37, 325-8, 331-4	1.4	11
71	Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. <i>American Journal of Ophthalmology</i> , 2002 , 133, 649-56	4.9	83
70	Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. <i>Ophthalmology</i> , 2002 , 109, 1377-82	7.3	272
69	How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy?. <i>Arthritis and Rheumatism</i> , 2002 , 46, 561		14
68	State of the art: Juvenile idiopathic arthritis. APLAR Journal of Rheumatology, 2002, 5, 29-34		2

(2011-2003)

67	The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. <i>Ophthalmology</i> , 2003 , 110, 1321-6	7.3	195
66	Detecting chloroquine retinopathy: electro-oculogram versus colour vision. <i>British Journal of Ophthalmology</i> , 2003 , 87, 902-8	5.5	34
65	Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. <i>Retina</i> , 2003 , 23, 503-12	3.6	47
64	Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2004 , 33, 336-51	5.3	94
63	[Analysis of 925 patients on long-term hydroxychloroquine or chloroquine treatment: results of ophthalmological screening]. <i>Journal Francais Dd</i> Ophtalmologie, 2004 , 27, 367-73	0.8	9
62	Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. <i>Documenta Ophthalmologica</i> , 2005 , 110, 111-20	2.2	48
61	[Ophthalmologic prevention of chloroquine and hydroxychloroquine induced retinopathy]. <i>Annales De Dermatologie Et De Venereologie</i> , 2005 , 132, 329-37	0.3	1
60	[Synthetic antimalarials]. Annales De Dermatologie Et De Venereologie, 2005, 132, 665-74	0.3	5
59	Hydroxychloroquine-induced retinopathy: a dermatologic perspective. <i>American Journal of Clinical Dermatology</i> , 2006 , 7, 171-5	7.1	7
58	Ocular manifestations of systemic lupus erythematosus: a clinical review. <i>Lupus</i> , 2006 , 15, 3-12	2.6	63
57	Abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retino-toxicity. <i>Eye</i> , 2006 , 20, 129-32	4.4	15
56	Chloroquine-induced bullß eye maculopathy in rheumatoid arthritis: related to disease duration?. <i>Clinical Rheumatology</i> , 2007 , 26, 1248-53	3.9	25
55	Ocular toxicity of hydroxychloroquine. Seminars in Ophthalmology, 2008, 23, 201-9	2.4	74
54	Ocular manifestations of systemic lupus erythematosus. <i>Current Opinion in Ophthalmology</i> , 2008 , 19, 512-8	5.1	56
53	[Antimalarials. A treatment option for every lupus patient!?]. <i>Zeitschrift Fur Rheumatologie</i> , 2009 , 68, 584, 586-90	1.9	4
52	Intravenous immunoglobulin in lupus panniculitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2010 , 38, 307-18	12.3	30
51	Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. <i>International Journal of Rheumatic Diseases</i> , 2010 , 13, e11	1 -2 5 ³	17
50	Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. <i>Ophthalmology</i> , 2011 , 118, 415-22	7.3	449

49	Retinal disorders in northern Brazilian patients treated with chloroquine assessed by multifocal ERG. <i>Documenta Ophthalmologica</i> , 2011 , 122, 77-86	2.2	3	
48	A case of severe hydroxychloroquine-induced retinal toxicity in a patient with recent onset of renal impairment: a review of the literature on the use of hydroxychloroquine in renal impairment. <i>Case Reports in Ophthalmological Medicine</i> , 2012 , 2012, 182747	0.7	15	
47	Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients. <i>Rheumatology International</i> , 2012 , 32, 743-8	3.6	2	
46	Drug Toxicity of the Posterior Segment. 2013 , 1532-1554		6	
45	The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. <i>Clinical Ophthalmology</i> , 2014 , 8, 1401-7	2.5	11	
44	Retinal damage in chloroquine maculopathy, revealed by high resolution imaging: a case report utilizing adaptive optics scanning laser ophthalmoscopy. <i>Korean Journal of Ophthalmology: KJO</i> , 2014 , 28, 100-7	1.2	10	
43	Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. <i>JAMA Ophthalmology</i> , 2014 , 132, 1199-208	3.9	38	
42	Chloroquine and Hydroxychloroquine Increase Retinal Pigment Epithelial Layer Permeability. <i>Journal of Biochemical and Molecular Toxicology</i> , 2015 , 29, 299-304	3.4	19	
41	Hydroxychloroquine Retinopathy. <i>Journal of Rheumatic Diseases</i> , 2015 , 22, 140	1.2		
40	The Diagnosis and Treatment of Systemic Lupus Erythematosus. <i>Deutsches A&#x0308;rzteblatt International</i> , 2015 , 112, 423-32	2.5	81	
39	Hydroxychloroquine-related retinal toxicity. <i>Rheumatology</i> , 2016 , 55, 957-67	3.9	57	
38	Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. <i>Scientific Reports</i> , 2017 , 7, 2046	4.9	62	
37	Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1142-1165	2.3	5	
36	Oral Manifestations of Systemic Diseases and Their Treatments. 2019 , 1523-1639			
35	Fluorescence Lifetimes in Patients With Hydroxychloroquine Retinopathy. 2019, 60, 2165-2172		8	
34	Sicherheitsmanagement der Therapie mit Antimalariamitteln: was bedeuten die neuen Empfehlungen fildie Praxis?. <i>Aktuelle Rheumatologie</i> , 2020 , 45, 314-318	0.1		
33	Natural history of COVID-19 and current knowledge on treatment therapeutic options. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 129, 110493	7.5	59	
32	[Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search]. Zeitschrift Fur Rheumatologie, 2020, 79, 18	6-1 9 4	6	

(2009-2020)

31	Current pharmacological treatments for COVID-19: WhatB next?. <i>British Journal of Pharmacology</i> , 2020 , 177, 4813-4824	8.6	137
30	Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 80, 1-9	1.9	13
29	Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. <i>Viruses</i> , 2021 , 13,	6.2	2
28	Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure: Case report and literature review. <i>Medicine (United States)</i> , 2021 , 100, e24919	1.8	3
27	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. <i>Food and Chemical Toxicology</i> , 2021 , 151, 112106	4.7	3
26	Oral Manifestations of Systemic Diseases and their Treatments. 2018, 1-117		2
25	Vision loss. 2010 , 55-101		1
24	Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19.		6
23	GNS561 exhibits potent antiviral activity against SARS-CoV-2 through autophagy inhibition. 2020,		2
22	Hydroxychloroquine retinopathy: is screening necessary?. <i>BMJ: British Medical Journal</i> , 1998 , 316, 716-7		16
21	Screening for hydroxychloroquine retinopathy. Screening should be selective. <i>BMJ: British Medical Journal</i> , 1998 , 317, 1388-9		10
20	Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. <i>BJGP Open</i> , 2020 , 4,	3.1	61
19	Hydroxychloroquine retinopathy: A review of imaging. <i>Indian Journal of Ophthalmology</i> , 2015 , 63, 570-4	1.6	16
18	ANTIMALARIALS AND IMMUNOSUPPRESSIVE THERAPIES. 2004 , 1273-1293		
17	Nutritional, Toxic and Pharmacologic Effects. 2005 , 407-447		1
16	Drug Toxicity of the Posterior Segment. 2006 , 1839-1856		1
15	Retinal Toxicity of Systemic Medications. 2008, 2213-2224		
14	SYSTEMIC LUPUS ERYTHEMATOSUS. 2009 , 1047-1062		

12	Hydroxychloroquine-induced retinopathy*. 2012 , 180-184		
11	Epidemiology of Hydroxychloroquine and Chloroquine Retinopathy. 2014, 95-106		
10	Natural History of Hydroxychloroquine and Chloroquine Retinopathy. 2014, 107-131		
9	Drug Induced Maculopathies. 2020 , 1-23		
8	Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown. <i>Indian Journal of Pharmacology</i> , 2020 , 52, 75-78	2.5	O
7	Sehstflungen. 2006 , 267-287		
6	Reversible blurred vision with hydroxychloroquine in a COVID-19 patient. <i>TNOA Journal of Ophthalmic Science and Research</i> , 2021 , 59, 404	0.1	
5	GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition <i>Viruses</i> , 2022 , 14,	6.2	О
4	When should we start screening for hydroxychloroquine retinopathy?. Rheumatology, 2022,	3.9	
3	Drug Induced Maculopathies. 2022 , 3739-3761		
2	Drug Induced Maculopathies. 2022 , 1-23		O
1	The Impact of Systemic Medications on Retinal Function. 2023 , 12, 115-157		О

Treatment of non-renal lupus. **2011**, 1307-1316.e4

13